Health Areas › Neurological Diseases

Neurological Diseases

Area 7 in the list of seventeen published by the Saudi National Institute of Health in June 2025. Order follows SNIH's published list: that number is SNIH's own position for the area; it is not a ranking by this site and it says nothing about how much research this area should receive.

This area is matched to research by its subject headings, Nervous System Diseases (C10), and to disease burden by the WHO cause-to-area table v0.4. The match is partial, so the burden shown is the burden of selected WHO proxy causes and no ratio is given.

A paper or study can count in more than one area. Areas as published by the Saudi National Institute of Health (SNIH), June 2025, applied to 2021–2025 retrospectively, for description only. A Saudi affiliation is not the same as research on the Saudi population.

Partial. Burden of selected WHO proxy causes. The two shares are shown side by side with no ratio.

Partial

Order follows SNIH's published list: area 7 of seventeen.

Coverage Of The Underlying Corpus · 2021–2025

On the same selection, before the area filter. Papers without MeSH terms stay in this coverage line; they are never in any area or in the grey row. It describes the corpus, not how completely this area’s research is captured.

Papers without MeSH terms cannot be assigned to any area, so this profile is never a complete count of the area’s research, and it does not measure how completely that research is captured. Coverage: records captured by the named sources that meet the published eligibility rules; coverage is not exhaustive.

Eligible publications with MeSH terms

60.6%

PubMed with OpenAlex · 2021–2025

Eligible publications matched to any area

41.3%

PubMed with OpenAlex · 2021–2025

The Burden This Area Carries

Burden Share & Research Share

Burden: WHO Global Health Estimates, 2023 · research: 2021–2025

Share of national disease burden: burden of selected WHO proxy causes

Source: WHO Global Health Estimates, 2023, through the WHO cause-to-area table v0.4. All-age disability-adjusted life years for one named year.

10.8%

WHO · 2023

Research share among MeSH-indexed eligible publications

Eligible publications in this area, 2021–2025, divided by all eligible publications with MeSH terms in the same selection, before the area filter. Shares across the seventeen areas do not sum to 100%.

10.4%

of the eligible publications with MeSH terms · 2021–2025

Research-share-to-burden-share ratio

Shown because this area is a close match. A ratio of 1 means equal shares under these definitions; it does not establish adequate research effort or funding, and it carries no judgement about what the right figure would be.

Not shown. Not yet computed, below the threshold for a reliable figure, or the only source is too old to print. The reason is always given.

—

Not shown the ratio is given only for a close match.

Recorded Research

Three Counts, Never One Total

Papers and registrations are counted separately, never added together.

A paper, a clinical trial and an observational registration are different kinds of record, so this area carries three separate counts. They are never added together.

Papers and registrations are different kinds of record. They are counted separately and never added together, anywhere on this site. Counts describe recorded activity; they do not assess quality, benefit or performance.

Registrations are ClinicalTrials.gov records; a listed site doesn't prove recruitment in Saudi Arabia.

Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.

Trials and observational studies are those listing a Saudi site. A listed site does not prove that participants were recruited in Saudi Arabia. Withdrawn studies and expanded-access records are not counted.

Publications

PubMed and OpenAlex · research-related papers with a Saudi affiliation carrying Nervous System Diseases (C10) · 2021–2025

PubMed with OpenAlex · 2021–2025 provisional

Clinical trials

ClinicalTrials.gov · interventional, listing a Saudi site · 2021–2025

ClinicalTrials.gov · 2021–2025 provisional

Observational studies

ClinicalTrials.gov · observational registrations listing a Saudi site · 2021–2025

ClinicalTrials.gov · 2021–2025 provisional

Publications By Year

Research-related papers in this area, by year of earliest publication. The axis starts at zero and ends at 2,000.

2021
2022
2023
2024
2025 provisional
Publications By Study Group

Research-related papers in this area, 2021–2025, in the five study groups. The axis starts at zero and ends at 2,000.

Interventional
Observational
Evidence synthesis
Laboratory and animal
Other designs
Clinical Trials By Phase

Trials in this area, 2021–2025. A trial registered across two phases counts in both. The axis starts at zero and ends at 100.

Early phase 1 0
Phase 1
Phase 2
Phase 3
Phase 4
Not applicable
Clinical Trials By Recruitment Status

Trials in this area, 2021–2025, by status as the registry records it on the day ClinicalTrials.gov processed the data. The axis starts at zero and ends at 100. Statuses open largest first.

Completed
Unknown
Recruiting
Active, not recruiting
Enrolling by invitation
Not yet recruiting
Suspended 0
Terminated 0
Observational Studies By Recruitment Status

Observational studies in this area, 2021–2025, by status as the registry records it. The axis starts at zero and ends at 2. Statuses open largest first.

Completed
Recruiting
Unknown
Active, not recruiting
Enrolling by invitation
Not yet recruiting 0
Suspended 0
Terminated 0

Industry

Industry In This Area

The area's three counts narrowed to industry: research papers coded industry-involved, industry-led clinical trials and industry-led observational studies, each with its share of the area's own count. They are three kinds of record and are never added together.

Industry in papers comes from each paper's own industry code; industry in registrations comes from the lead sponsor. They are different measures of different records and are never combined.

Industry in registrations means a lead sponsor that is a company making or selling health products (drugs, vaccines, biotechnology, devices, diagnostics, health software or medical nutrition), as the industry guide defines it in its section two, or a contract research organisation with such a company listed as collaborator. Hospital groups and other providers that ClinicalTrials.gov labels “industry” are not counted. Withdrawn studies are not counted.

Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.

Counts describe recorded activity; they do not measure investment, quality or performance.

Industry involvement in papers is a lower bound.

Industry involvement is identified from the paper's own record and registration; it does not establish financial investment and is a lower bound.

Industry-involved publications

3% of the 4,253 research papers in the area

PubMed with OpenAlex · 2021–2025 provisional

Industry-led clinical trials

18% of the 95 clinical trials in the area

ClinicalTrials.gov · 2021–2025 provisional

Industry-led observational studies

50% of the 8 observational studies in the area

ClinicalTrials.gov · 2021–2025 provisional

Companies

Companies Leading Studies In This Area

Every company credited with at least one industry-led clinical trial or observational study in this area, 2021–2025, with both counts: two counts, never one total. Each study is credited to one company, exactly as the industry-led counts decide it: its lead sponsor or, for a contract research organisation's study, its company collaborator listed in the registration. So the companies' studies add up to the area's industry-led counts. A study in several areas counts in each. Names are shown as registered, with no grouping into parent companies.

There is no rank column. The list opens with the most clinical trials, ties A–Z. Every count above zero opens its records.

Only studies listing a Saudi site are counted. Industry in registrations means a lead sponsor that is a company making or selling health products (drugs, vaccines, biotechnology, devices, diagnostics, health software or medical nutrition), as the industry guide defines it in its section two, or a contract research organisation with such a company listed as collaborator. Hospital groups and other providers that ClinicalTrials.gov labels “industry” are not counted. Withdrawn studies are not counted.

Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.

The counts describe registered activity; they do not measure investment, quality or performance.

Showing 2021–2025 provisional

Registrations are ClinicalTrials.gov records; a listed site doesn't prove recruitment in Saudi Arabia.

A listed site does not prove that participants were recruited in Saudi Arabia. Withdrawn studies and expanded-access records are not counted.

Companies Credited With Industry-Led Studies In Neurological Diseases, 2021–2025.
CompanyClinical trialsObservational studies
Novartis Pharmaceuticals 0
Biogen 0
Sanofi 0
Travere Therapeutics, Inc. 0
argenx 0
Cyclo Therapeutics, Inc. 0
iamYiam Limited 0
Kyverna Therapeutics 0
Merck Sharp & Dohme LLC 0
Ultragenyx Pharmaceutical Inc 0
AstraZeneca 0
Bayer 0
Novo Nordisk A/S 0
Orphalan 0

Institutions

Institutions In This Area

Every institution on the approved list with at least one research-related publication, clinical trial or observational study in this area, 2021–2025. Three counts, never one total: a paper, a clinical trial and an observational registration are different kinds of record.

They are counted exactly as on Institutions & Clusters: publications in full; a parent institution's row also counts its units' papers and studies, so rows overlap and are never added together; clinical trials and observational studies count registrations listing the institution as a site, and a listed site does not prove that participants were recruited there. Institutions are named as OpenAlex records them.

There is no rank column. The list opens with the most publications, ties A–Z; the switch orders it by clinical trials, observational studies or A–Z. Every count above zero opens its records. No citation measure is given here.

90 of the area's 4,253 research papers have no Saudi institution identified and count in no institution · PubMed with OpenAlex · 2021–2025 provisional

Institutions With Research In Neurological Diseases, 2021–2025.
InstitutionPublicationsClinical trialsObservational studies
King Saud University 0
King Abdulaziz University 0
King Saud bin Abdulaziz University for Health Sciences 0 0
King Khalid University 0
Prince Sattam Bin Abdulaziz University 0
King Faisal Specialist Hospital & Research Centre
King Abdullah International Medical Research Center 0
Princess Nourah bint Abdulrahman University 0 0
Imam Abdulrahman Bin Faisal University 0
National Guard Health Affairs 0 0
Umm al-Qura University 0
Qassim University 0 0
Jouf University 0 0
Taif University 0 0
Alfaisal University 0
Jazan University 0
King Abdulaziz Medical City
King Fahd Medical City
Taibah University 0
University of Tabuk 0 0
King Faisal University 0 0
King Saud Medical City 0
Shaqra University 0 0
Imam Mohammad ibn Saud Islamic University 0 0
Majmaah University
King Fahad Specialist Hospital (location not recorded) 0 0
Ministry of Health 0 0
Riyadh Armed Forces Hospital 0 0
Najran University 0 0
University of Ha'il 0
University of Jeddah 0 0
University of Bisha 0 0
King Abdullah University of Science and Technology 0 0
Almaarefa University 0 0
King Salman Center for Disability Research 0 0
Batterjee Medical College 0
King Abdul Aziz University Hospital 0
Northern Border University 0 0
King Fahd Hospital of the University 0
King Khaled Eye Specialist Hospital 0 0
Jeddah First Health Cluster 0 0
King Abdullah Medical City 0
Buraydah Colleges 0 0
King Abdulaziz Hospital (Jeddah First Health Cluster) 0 0
Saudi Aramco (Saudi Arabia) 0 0
Saudi Aramco Medical Services Organization 0 0
Security Forces Hospital 0
King Abdulaziz City for Science and Technology 0 0
Al Baha University 0 0
King Fahad Hospital Jeddah 0 0
Armed Forces Hospital (location not recorded) 0 0
King Fahd Armed Forces Hospital 0
Asir Central Hospital 0 0
Riyadh Elm University 0 0
Saudi Electronic University 0 0
Effat University 0 0
Armed Forces Hospital Southern Region 0 0
Sulaiman Al Rajhi Colleges 0 0
Dar Al Uloom University 0 0
Fakeeh College for Medical Sciences 0 0
King Fahd Military Medical Complex 0 0
King Khalid University Hospital 0 0
Qatif Central Hospital 0 0
University of Hafr Al-Batin 0 0
Ibn Sina National College for Medical Studies 0 0
King Fahad Central Hospital (location not recorded) 0 0
Prince Sultan Military College of Health Sciences 0 0
Prince Sultan University 0 0
Mohammed Almana College for Medical Sciences 0 0
Soliman Fakeeh Hospital 0
King Fahd University of Petroleum and Minerals 0 0
Prince Mohammad bin Fahd University 0 0
Hera General Hospital 0 0
Prince Mohammed bin Abdulaziz Hospital 0 0
East Jeddah Hospital 0 0
Islamic University of Madinah 0 0
Maternity and Children's Hospital (location not recorded) 0 0
King Fahad Hospital Hufūf 0 0
Saudi Food and Drug Authority 0 0
International Medical Center in Jeddah 0 0
Naif Arab University for Security Sciences 0 0
Inaya Medical Colleges 0 0
Ministry of Defense 0 0
Ministry of Education 0 0
Dhahran Health Center 0 0
King Khaled Hospital (location not recorded) 0 0
Royal Commission for Jubail and Yanbu 0 0
Saudi Water Authority 0 0
Al-Ghad International Health Sciences Colleges 0 0
Al-Thagher General Hospital 0 0
Bugshan Hospital 0 0
Dammam Central Hospital 0 0
Dr. Samir Abbas Hospital 0 0
Fahd bin Sultan University 0 0
General Directorate of Health Affairs in Riyadh Region 0 0
Hevolution Foundation 0 0
King Abdulaziz Hospital (location not recorded) 0 0
North Private College of Nursing 0
North West Armed Forces Hospital 0 0
Northern Area Armed Forces Hospital 0 0
Onaizah Colleges 0 0
Royal Commission Medical Center 0 0
Saudi Commission for Health Specialties 0 0
Saudi Health Council 0 0
University of Business and Technology 0 0
Yanbu Industrial College 0 0

Clinical Trials

Clinical Trials By Intervention Type

The area's clinical trials, 2021–2025, by ClinicalTrials.gov's intervention type, with the industry-led part. A trial with several intervention types counts in each, so the bars are never added together and can sum to more than the area's 95 trials. “Other” is the registry's own type; it comes last, as “Not recorded” would. The list opens largest first, ties A–Z. Each count above zero opens its records. Observational studies are not shown by type.

The axis starts at zero and ends at 100.

All trials Industry-led trials

Device ·
Drug ·
Biological ·
Dietary Supplement ·
Procedure ·
Behavioural · 0
Genetic ·
Other ·

ClinicalTrials.gov · 2021–2025 provisional

National Health Facts · Saudi Arabia

Neurological Diseases: National Health Facts

National health facts checked against their sources: 4 November 2026 to 5 November 2026.

Each card names its source in short; its ⓘ gives the full source. The full view below holds every fact with its full source.

Estimate. Estimated or modelled by its source, not counted directly.

National figures for all residents unless stated.

At A Glance

25%

of this area's burden is from migraine, and 22% from stroke

Estimate WHO · 2023

Estimate WHO Global Health Estimates, 2023 · 2023

About 4,200

stroke deaths in 2023 (also counted in Cardiovascular Diseases)

Estimate WHO · 2023

Estimate WHO Global Health Estimates, 2023 · 2023 · also counted in Cardiovascular Diseases

About 560

epilepsy deaths in 2023

Estimate WHO · 2023

Estimate WHO Global Health Estimates, 2023 · 2023

Show Health Facts & SourcesHide Health Facts & Sources

Burden

Lost healthy life by condition within this area, 2023 (WHO estimates, WHO causes matched to the area by the project's cause table v0.4). The area's share of national burden appears in the profile's burden comparison lower down. DALYs are the years of healthy life lost to illness, disability or early death.

Migraine 25%
Stroke 22%
Hearing loss 18%
Epilepsy 10%
Alzheimer disease and other dementias 3%
Brain and nervous system cancers 3%

Source: WHO Global Health Estimates, 2023

  • 4,235 StrokeWHO Global Health Estimates, 2023 · 2023 · 2,286 to 6,828, uncertainty interval
  • 564 EpilepsyWHO Global Health Estimates, 2023 · 2023 · 314 to 894, uncertainty interval
  • 523 Brain and nervous system cancersWHO Global Health Estimates, 2023 · 2023 · 322 to 887, uncertainty interval
  • 441 Alzheimer disease and other dementiasWHO Global Health Estimates, 2023 · 2023 · 87 to 1,248, uncertainty interval

What Is Not Measured

  • No suitable national prevalence estimate identified.

Sources Of These Facts

About These Figures

How This Area Is Matched

A paper belongs to this area when any of its subject headings is one of the area's headings or sits beneath it. Registered studies use the same headings, applied to the conditions the registry records. Only records carrying subject headings can be assigned at all, and coverage is reported for every selection.

What This Page Does Not Say

Nothing here assesses quality, benefit or performance, and no figure on it should be read as a target. The research-share-to-burden-share ratio compares two shares; it does not establish that research in this area is too much, too little or correctly aimed. Counts describe what is recorded, which is not the same as what was done.

Where The Figures Come From

Publications from PubMed matched with OpenAlex; trials and observational studies from ClinicalTrials.gov. Area assignment follows the SNIH 17-area research dictionary v1.2; burden follows the WHO cause-to-area table v0.4. Both are published in full on the methods page.

* Not final: counts for these years usually rise at later updates, as many studies are registered after they start and recent papers are still being added. On this page: trials and publications 2025; observational studies 2024–2025.